期刊
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
卷 12, 期 6, 页码 1117-1123出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.dsx.2018.06.003
关键词
Key words; Sodium glucose cotransporter 2; Kidney; Nephroprotection; Acute kidney injury; Ketones
资金
- Astra-Zeneca
- Bristol-Myers Squibb
- Pfizer
- Lilly
- Abbott
- Amgen
- AstraZeneca
- Novartis
- Vianex
- Teva
- MSD
- Sanofi-Aventis
- Boehringer Ingelheim
- Eli-Lilly
- GSK
Aims: Numerous clinical trials have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors exert a favorable effect on the indices of renal function (albuminuria, glomerular filtration rate decline over time) and the incidence of hard renal endpoints such as renal death or time to initiation of renal replacement therapy. Materials and methods: In this review, we describe in detail the evidence regarding the nephroprotective mechanisms of SGLT2 inhibitors and describe the risk factors that may predispose to the development of acute kidney injury in patients receiving these drugs. Results: Although the impact of these drugs on renal hemodynamics seems to represent the most important renoprotective mechanism of action, many other effects of these compounds, including beneficial effects on metabolism and blood pressure, have been proposed to contribute to the observed clinical benefit. Conclusions: SGLT2 inhibitors clearly act beneficially in terms of kidney function with many proposed mechanisms. (c) 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据